XLV Fund - Health Care Select Sector SPDR ETF Overview - MarketWatch

Open $81.88
Day Range 81.73 - 83.19
52 Week Range 74.45 - 91.79
Market Cap n/a
Shares Outstanding 185.82M
Total Net Assets $15.28B
Beta 0.99
NAV $81.84
NAV Date May 10, 2018
Net Expense Ratio 0.14%
Turnover % 4%
Yield 1.44%
Dividend $0.30
Ex-Dividend Date Mar 16, 2018
Average Volume 8.88M

YTD Lipper Ranking:Quintile 4 (78th percentile)

3 Total Returns
3 Consistent Return
4 Preservation
4 Tax Efficiency
5 Expense

Highest
5
4
3
2
1
Lowest

MarketWatch
Other Dow Jones

Trump Today: President lays out drug price plan, talks mileage standards with auto makers

May. 11, 2018 at 3:45 p.m. ET
by Steve Goldstein

President Trump’s big drug price speech boosts pharma stocks

May. 11, 2018 at 3:39 p.m. ET
by Emma Court

Drug stocks slip, then swing back even higher after Trump unveils drug cost cutting plan

Healthcare stocks dipped after President Donald Trump started presenting his plan to cut prescription drug costs, then bounced sharply to trade even higher than pre-speech levels. The SPDR Health Care Select Sector ETF was up about 0.5% before Trump's speech began, then slid to be down 0.1% swinging higher to be up 1.1% at a new intraday high. Among shares of the ETF's four most heavily weighted components, which were all also Dow Jones Industrial Average components: Johnson & Johnson went from a gain of 0.8% to a gain of 0.5%, but is now up 0.9%; Pfizer Inc. was up 0.8%, then up 0.2%, and now up 1.2%; UnitedHealth Group Inc. went from a 0.8% gain to a 0.3% loss, but was now up 1.3%; and Merck & Co. Inc. was up 1.2%, then up just 0.5%, and was now up 2.3%. Some changes to policy announced by Trump and Health and Human Services Secretary Alex Azar included drug price negotiation by government programs, an end to the "gag rule" on pharmacists--who cannot disclose if drug products can be bought for cheaper without using a health plan -- and disclosure of drugs' list prices pharmaceutical advertisements.

May. 11, 2018 at 2:41 p.m. ET
by Tomi Kilgore

SPDR Health Care ETF up 0.8%, reversing post-Trump-speech decline of as much as 0.1%

May. 11, 2018 at 2:23 p.m. ET
by Tomi Kilgore

Healthcare stocks dip after Trump's drug speech starts, then bounces to trade higher the pre-speech levels

May. 11, 2018 at 2:22 p.m. ET
by Tomi Kilgore

Baxter boosts quarterly dividend by 19%, effective July

Baxter International Inc. said Tuesday it will raise its quarterly dividend by 19% to 19 cents a share, from 16 cents a share. The healthcare products company's new dividend will be payable July 2 to shareholders of record on June 1. Based on Monday's stock closing price of $70.33, the new annual dividend rate implies a dividend yield of 1.08%, compared with the dividend yield of the SPDR Health Care Select Sector ETF of 1.54% and the implied S&P 500 dividend yield of 1.96%, according to FactSet. Baxter's stock, which was still inactive in premarket trade, has rallied 8.8% year to date, while the healthcare ETF has lost 2.2% and the S&P 500 has slipped less than 0.1%.

May. 8, 2018 at 9:09 a.m. ET
by Tomi Kilgore

These 5 stocks offer a great balance between the growth of tech and the stability of health care

May. 3, 2018 at 10:03 a.m. ET
by Jeff Reeves

Drugmakers eye a new threat to sales but say it hasn’t affected them — yet

May. 3, 2018 at 9:11 a.m. ET
by Emma Court

S&P 500 to fall another 5% in coming months as economy weakens: Stifel

The S&P 500 should continue to fall over the next couple months, by nearly 5%, as weaker global economic growth leads to declining equity prices and Treasury yields, said Stifel Nicolaus macro and portfolio strategist Barry Bannister. He said he targets a decline to 2,520 in the S&P 500 by the middle of the third quarter, which is 4.7% below current levels, 12.3% below the Jan. 26 record close of 2,872.87 and would be the lowest close since Sept. 29, 2017. He also expects the 10-year Treasury yield falling to 2.6%, below the current level of 2.97%, as a weaker global economy and "risk-off" activity fuels flows into Treasury bonds and the U.S. dollar. Within this scenario, Bannister recommends being overweight utilities , consumer staples , healthcare and real estate investment trusts , which are defensive and higher-yielding sectors, while being underweight energy , capital goods and financials , which are more cyclical. The S&P 500 fell 0.4% in morning trade, and has shed 8.2% from its record close.

May. 1, 2018 at 10:13 a.m. ET
by Tomi Kilgore

Aetna beats profit expectations, but sales come up a bit shy

Aetna Inc. reported Tuesday that it swung to first-quarter net income of $1.21 bln, or $3.67 a share, from a loss of $381 million, or $1.11 a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to $3.19, above the FactSet consensus of $2.97. Revenue rose 1% to $15.34 billion, just shy of the FactSet consensus of $15.35 billion, as premiums declined to $13.07 billion from $13.76 billion while fees increased to $2.06 billion from $1.48 billion. Healthcare segment revenue rose to $15.1 billion from $14.8 billion, topping expectations of $14.5 billion. The healthcare benefits company's stock was still not active in premarket trade. It has lost 4.5% over the past three months, while the SPDR Health Care Select Sector ETF has shed 6.7% and the S&P 500 has slipped 4.3%.

May. 1, 2018 at 7:01 a.m. ET
by Tomi Kilgore

Premium

U.S. benchmarks tag the breakdown point as jagged April nears conclusion

U.S. stocks are higher early Monday, rising after a solid batch of earnings reports, and even as the U.S. dollar challenges its 200-day moving average from underneath. Against this backdrop, each big three U.S. benchmark has ventured atop near-term resistance with the monthly close pending Monday.

Apr. 30, 2018 at 11:33 a.m. ET
by Michael Ashbaugh

Merck's stock surges to lead Dow's gainers after Goldman turns bullish

Shares of Merck & Co. Inc. ran up $1.61, or 2.7%, to a near three-month high in afternoon trade Monday, enough to pace the Dow Jones Industrial Average's gainers, after Goldman Sachs turned bullish on the drugmaker, citing the success of its blockbuster cancer drug Keytruda. The price gain was adding about 11 points to the price of the Dow, which was up 3 points. Analyst Jami Rubin raised her rating to buy, added the shares to Americas Conviction List and boosted her stock price target to $73 from $63. Rubin had previously had a neutral rating on Merck for at least the past three years. "We believe the narrative for this company is quickly changing with the success of Keytruda," which she believes has the potential to be a $16 billion asset by 2025, Rubin wrote in a note to clients. She said Keytruda could drive a "significant shift" in product mix from a large primary care to a specialty biopharmaceutical company. Merck's stock has climbed 7.4% year to date, while the SPDR Health Care Select Sector ETF has slipped 0.2% and the Dow has lost 1.1%.

Apr. 23, 2018 at 2:04 p.m. ET
by Tomi Kilgore

Premium

S&P 500 knifes atop major resistance, breakout gets low marks for style

Broadly speaking, the big three U.S. benchmarks have made technical progress amid a rally attempt that persistently gets low style marks. Nonetheless, the S&P 500 has reclaimed major resistance — S&P 2,695, matching the breakdown point — and its backdrop supports a guardedly bullish-leaning bias to the extent the break higher is sustained.

Apr. 18, 2018 at 12:03 p.m. ET
by Michael Ashbaugh

Abbott Labs beats profit and sales expectations, shares slip

Shares of Abbott Laboratories slipped 0.8% in premarket trade Wednesday, although the health care company reported first-quarter profit and sales that rose above expectations. Net income slipped to $418 million, or 23 cents a share, from $419 million, or 24 cents a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share rose to 59 cents from 48 cents, to beat the FactSet consensus of 58 cents. Revenue rose 16.7% to $7.39 billion, above the FactSet consensus of $7.29 billion, as nutrition and diagnostics sales topped expectations while established pharmaceuticals revenue came up a bit shy. Looking ahead, the company expects second-quarter adjusted EPS of 70 cents to 72 cents, surrounding the FactSet consensus of 71 cents, and affirmed its 2018 adjusted EPS guidance range of $2.80 to $2.90. The stock has gained 4.8% year to date through Tuesday, while the SPDR Health Care Select Sector ETF has edged up 0.6% and the S&P 500 has tacked on 1.2%.

Apr. 18, 2018 at 8:00 a.m. ET
by Tomi Kilgore

Eli Lilly's stock rallies after BMO raises rating, price target

Shares of Eli Lilly & Co. rallied 1.2% in morning trade Friday, after BMO Capital backed away from its bearish stance that it's kept for the past year, given the belief that previous concerns are now mostly reflected in the stock. Analyst Alex Afraei raised his rating to market perform, after being at underperform since April 17, 2017, and raised his stock price target to $79 from $73. Afraei said now that his concerns--downside risk for diabetes treatment Humalog, a cautious outlook for lung cancer treatment Verzenio and uncertainty surrounding arthritis drug baricitinib--have mostly materialized and have been priced into the stock, "the risk/reward is more balanced going forward." The stock has declined 6.5% over the past 12 months, while the SPDR Health Care Select Sector ETF has rallied 11.1% and the S&P 500 has climbed 14.7%.

Apr. 13, 2018 at 9:58 a.m. ET
by Tomi Kilgore

Premium

S&P 500 maintains 200-day average (again), latest corrective bounce underway

U.S. stocks are firmly higher early Monday, rising amid waning trade-policy concerns and respectable overseas market strength. Against this backdrop, the S&P 500 is traversing a wide April range, capped by major resistance, and thus far underpinned by the 200-day moving average.

Apr. 9, 2018 at 11:34 a.m. ET
by Michael Ashbaugh

Merck's stock surges after positive Keytruda trial results

Shares of Merck & Co. Inc. surged 2.6% in premarket trade Monday, after the drug maker said its cancer treatment Keytruda met the primary endpoint of a phase 3 trial evaluating the Keytruda as monotherapy for the first-line treatment of metastatic non-small cell lung cancer. The primary endpoint was overall survival. An independent data monitoring committee (DMC) determined that treatment with Keytruda resulted in significantly longer overall survival than platinum-based chemotherapy in tested patients. Based on the DMC's finding, the trial will continue to evaluation progression-free survival, which is the secondary endpoint. Merck's stock has lost 5.2% year to date through Monday, while the SPDR Health Care Select Sector ETF has shed 3.4% and the Dow Jones Industrial Average has slipped 3.2%.

Apr. 9, 2018 at 7:00 a.m. ET
by Tomi Kilgore

CVS is making a medical device, showing how health-care companies are doing more

Apr. 8, 2018 at 11:57 a.m. ET
by Emma Court

MannKind's stock sinks after direct stock offering

Shares of MannKind Corp. sank 15% in premarket trade Friday, after the maker of inhaled therapeutic products announced a direct offering of 14 million shares, and warrants to buy an additional 14 million shares. The shares and warrants, which are exercisable at $2.38 a share six months affter issuance, were being sold together to "select healthcare dedicated institutional investors," at a price of $2.00 for one share and one warrant. That price is 16% below Thursday's stock closing price of $2.38. The offering could increase the shares outstanding by 11.6%, or by 23.2% if all the warrants are exercised. The company plans to use the proceeds from the offering for general corporate purposes. The stock has lost 3.6% over the past three months through Thursday, while the SPDR Health Care Select Sector ETF has shed 4.0% and the S&P 500 has slipped 2.9%.

Apr. 6, 2018 at 7:49 a.m. ET
by Tomi Kilgore

These sectors and stocks could suffer the most collateral damage from China trade war

Apr. 5, 2018 at 6:59 a.m. ET
by Tomi Kilgore

Amazon Is Now a $700 Billion Stock-Market Gorilla

Jan. 31, 2018 at 12:19 p.m. ET
on The Wall Street Journal

Health-Care Stocks Poised for More Gains

Sep. 11, 2017 at 3:10 p.m. ET
on Barron's

Tech’s Weakness Can’t Kill This Bull Market

Jul. 6, 2017 at 7:31 a.m. ET
on Barron's

Health-Care Stocks Get a Boost From Senate Bill Rollout

Jun. 22, 2017 at 12:22 p.m. ET
on The Wall Street Journal

Multiple Sector Breakouts Show This Bull Has Legs

Jun. 8, 2017 at 7:54 a.m. ET
on Barron's

How to Pick a Health-Care ETF

May. 13, 2017 at 2:16 a.m. ET
on Barron's

Biotech ETFs Sink After House Passage of Health-Care Bill

May. 11, 2017 at 3:52 p.m. ET
on The Wall Street Journal

Health-Care Investors Are Too Complacent

Mar. 24, 2017 at 12:21 p.m. ET
on The Wall Street Journal

Goldman Says Buy Health-Care, Retail Volatility Before Trump Address

Feb. 22, 2017 at 1:11 p.m. ET
on The Wall Street Journal

Stock Pickers’ Delight: S&P 500 Correlations Plunge

Dec. 19, 2016 at 2:04 p.m. ET
on The Wall Street Journal

How to Play the Great Trump Market Rotation

Nov. 9, 2016 at 4:19 p.m. ET
on Barron's

Payouts Will Benefit as Buybacks Lose Favor

Oct. 15, 2016 at 12:20 a.m. ET
on Barron's

Health Care Stocks Are Looking Sick, Charts Say

Aug. 30, 2016 at 5:12 p.m. ET
on Barron's

Don’t Chase This Rally; Weak Outlook for Stocks

Jul. 4, 2016 at 8:55 a.m. ET
on Barron's

Markets: What Everyone Knows That Isn’t So

Apr. 2, 2016 at 1:40 a.m. ET
on Barron's

Utilities Sport Payout Power in First Quarter

Apr. 2, 2016 at 12:17 a.m. ET
on Barron's

Hospital Stocks Can Rally Amid Health-Care Slump

Oct. 27, 2015 at 12:29 a.m. ET
on Barron's

Dow ‘Death Cross’ Stirs Anxiety in Fragile Market

Aug. 13, 2015 at 10:38 a.m. ET
on Barron's

Bulls Firmly in Control as Stocks Plunge and Soar

Apr. 30, 2015 at 8:24 a.m. ET
on Barron's

The New Safe Stocks

Apr. 24, 2015 at 8:48 p.m. ET
on Barron's

Other News
Press Releases

Drug sector on the move after Trump speech

May. 11, 2018 at 3:23 p.m. ET
on Seeking Alpha

Trump Strikes At PBMs, Insurers, Drugmakers With Plans To Lower Consumer Prices

May. 11, 2018 at 1:34 p.m. ET
on benzinga.com

Trump speech on drug prices light on specifics

May. 11, 2018 at 2:25 p.m. ET
on Seeking Alpha

Trump plan on drug prices to be announced this afternoon

May. 11, 2018 at 10:22 a.m. ET
on Seeking Alpha

What Were the Hiring and Firing Trends in March?

The total separations for March came in at 5.3 million at a rate of 3.6% of the total workforce.

May. 10, 2018 at 8:14 a.m. ET
on MarketRealist.com

Bespoke's Sector Weightings Report - May 2018

May. 9, 2018 at 3:00 a.m. ET
on Seeking Alpha

FDA Approves JNJ’s Darzalex in Combination with VMP

Yesterday, the FDA approved Darzalex in combination with VMP for the treatment of newly diagnosed multiple myeloma in cases where patients are ineligible for autologous stem cell transplants.

May. 8, 2018 at 2:38 p.m. ET
on MarketRealist.com

Analyzing Merck’s Revenue in 1Q18

Merck (MRK), one of the largest pharmaceutical companies worldwide, reported its 1Q18 results on May 1.

May. 8, 2018 at 11:47 a.m. ET
on MarketRealist.com

Valuation Dashboard: Healthcare - Update

May. 7, 2018 at 1:37 p.m. ET
on Seeking Alpha

Financial Gravity Companies, Inc. Buys SPDR Select Sector Fund - Health Care, SPDR S&P ...

Financial Gravity Companies, Inc. Buys SPDR Select Sector Fund - Health Care, SPDR S&P Global Natural Resources, iShares Core MSCI Emerging Markets, Sells SPDR S&P 500, SPDR Bloomberg Barclays Intl Treasury Bd, iShares 1-3 Year Treasury Bond ETF

May. 4, 2018 at 10:38 p.m. ET
on GuruFocus.com

What Happened in the Stock Market Today

May. 3, 2018 at 5:03 p.m. ET
on Motley Fool

Which Sector Posted Major Job Gains in April?

The US employment market could be overheating. Businesses are adding more than 200,000 jobs per month despite rising trade tension.

May. 3, 2018 at 8:39 a.m. ET
on MarketRealist.com

Industrials, Technology Beating Earnings At The Highest Rate

May. 3, 2018 at 2:48 a.m. ET
on Seeking Alpha

Mounting Evidence of Inflation Firming Up

The U.S. Commerce Department reported retail sales fell in February for the third month in a row, while the University of Michigan Consumer Sentiment Index jumped to a 14-year high…

May. 2, 2018 at 10:57 a.m. ET
on MarketRealist.com

Merck & Co.’s 1Q18 Earnings: Revenues up 6%

Merck & Co. beat Wall Street analysts’ estimates for earnings per share (or EPS) today but missed analysts’ estimates for revenues.

May. 1, 2018 at 3:41 p.m. ET
on MarketRealist.com

Jim Chanos: ‘Winter Is Coming to the US Health Care System’

Jim Chanos has a bearish view on the healthcare sector. In a recent interview, he disclosed that he has a short position in Envision Healthcare (EVHC).

May. 1, 2018 at 9:41 a.m. ET
on MarketRealist.com

Merck & Co.’s 1Q18 Earnings: Analysts’ Estimates

Merck & Co. (MRK) is set to release its 1Q18 earnings tomorrow. Here's what you need to know!

Apr. 30, 2018 at 1:38 p.m. ET
on MarketRealist.com

Best Sector ETFs for May: Getting Defensive

Apr. 30, 2018 at 8:19 a.m. ET
on Benzinga.com

Don't Sell in May and Go Away: Follow These ETF Strategies

Investors could follow some ideas that could lead to a winning portfolio during this soft six-month period.

Apr. 30, 2018 at 10:33 a.m. ET
on Zacks.com

Sector Spotlight: Healthcare - The More Things Change...

Apr. 27, 2018 at 5:17 a.m. ET
on Seeking Alpha

No Headlines Available

Company	Symbol	Total Net Assets
Johnson & Johnson	JNJ	10.81%
UnitedHealth Group Inc.	UNH	6.84%
Pfizer Inc.	PFE	6.7%
AbbVie Inc.	ABBV	5.72%
Merck & Co. Inc.	MRK	4.59%
Amgen Inc.	AMGN	4.13%
Bristol-Myers Squibb Co.	BMY	3.37%
Medtronic PLC	MDT	3.37%
Gilead Sciences Inc.	GILD	3.19%
Abbott Laboratories	ABT	2.76%

View more holdings As of 02/28/2018

Category	Health/Biotech
Portfolio Style	Health/Biotech
Fund Status	Open
Fund Inception	December 16, 1998
Managers	Hancock Feehily Schneider

The Fund seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of the Health Care Select Sector Index. Under normal market conditions, the fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. (See Full Profile)

Date	Income Distribution
YTD	$0.29
2017	$1.21
2016	$1.1
2015	$1.03
2014	$0.92
2013	$0.84
2012	$0.8
2011	$0.68
2010	$0.57
2009	$0.57
2008	$0.58

Dow	24,830.00	90.47	0.37%
S&P 500	2,727.68	4.61	0.17%
Nasdaq	7,402.88	-2.09	-0.03%
GlobalDow	3,108.57	19.85	0.64%
Gold	1,319.10	-3.20	-0.24%
Oil	70.56	-0.80	-1.12%

Health Care Select Sector SPDR ETF

$ 83.03

Customize MarketWatch

No Items in Watchlist

No Saved Watchlists

Uh oh

No Recent Tickers

SPDR Health Care ETF up 0.8%, reversing post-Trump-speech decline of as much as 0.1%

Healthcare stocks dip after Trump's drug speech starts, then bounces to trade higher the pre-speech levels

Stocks

Columns

Authors

Topics

^$ 83.03